Summary

This article presents results from the Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy trial [ODYSSEY FH I; NCT01623115] and the Study of Alirocumab (REGN727/ SAR236553) in Patients With HeFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) trial [ODYSSEY FH II; NCT01709500].